(NYSE: EBS) Emergent Biosolutions's forecast annual revenue growth rate of -18.55% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3.09%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.36%.
Emergent Biosolutions's revenue in 2025 is $1,043,600,000.On average, 1 Wall Street analysts forecast EBS's revenue for 2025 to be $46,186,472,100, with the lowest EBS revenue forecast at $46,186,472,100, and the highest EBS revenue forecast at $46,186,472,100.
In 2026, EBS is forecast to generate $59,340,651,039 in revenue, with the lowest revenue forecast at $53,748,556,008 and the highest revenue forecast at $64,932,746,070.